Turner syndrome screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Turner syndrome}}
{{Turner syndrome}}
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}}{{Akash}}
==Overview==
==Overview==


There is insufficient evidence to recommend routine screening for [disease/malignancy].  
Screening for complications of [[Turner syndrome]] starts as early as a [[prenatal]] visit. Abnormal maternal [[serum]] screening tests or an [[ultrasound]] detecting [[structural anomalies]] such [[shortened limbs]], [[cystic hygromas]], [[congenital heart defects]] or increased [[swelling]] of the hands or feet may point towards a diagnosis of [[Turner syndrome]]. As the years progress, screening involves a multidisciplinary combination of lab investigations (such as [[serum]] [[gonadotrophins]], [[liver function tests]], [[renal function tests]], etc), referral to other departments ([[cardiology]], [[endocrinology]], [[ophthalmology]], etc) and tools such as [[DEXA scans]], [[X-rays]], [[echocardiography]], etc.  


OR
==Screening==
 
According to the [guideline name], screening for [disease name] is not recommended.
 
OR


According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
*The ‘Diagnostic study of choice’ page in this microchapter helps to integrate the below screening modalities in a clinical setting.
==Screening==
*In addition, frequent referral to departments such as [[cardiology]], [[nephrology]], [[embryology]], [[genetics]], [[endocrinology]], [[otorhinolaryngology]], [[ophthalmology]], [[dermatology]] and [[rheumatology]] ensures that a detail physical examination can be done to catch early signs of associated conditions seen in [[Turner syndrome]].
There is insufficient evidence to recommend routine screening for [disease/malignancy].
*Screening newborns usually first involves a bed side [[ultrasonography]] which may reveal [[nuchal translucency]], [[structural abnormalities]] such as [[shortened limbs]], [[lymphedema]] of hands and feed, [[cystic hygroma]] and [[cardiac defects]].
*This is used along with a maternal [[serum]] screening test which detects high [[inhibin B]], low [[unconjugated estriol]], high [[human chorionic gonadotrophin]] and low [[alpha feto protein]].
*Once a diagnosis has been established, screening is aimed at detecting complications.
*Individuals on [[growth hormone]] should be screened regularly with forward bend tests and [[X-rays]] as the therapy exposes underlying [[scoliosis]].
*[[echocardiography]] for [[cardiac structural abnormalities]] especially [[aortic dilation]] that predisposes the individual to [[aortic dissection]] and sudden [[cardiac death]].  
**The [[aortic severity index]] is a useful [[prognostic]] indicator when assessing for the risk of [[aortic dilatation]]. <ref name="pmid29344338">{{cite journal| author=Shankar RK, Backeljauw PF| title=Current best practice in the management of [[Turner syndrome]]. | journal=Ther Adv Endocrinol Metab | year= 2018 | volume= 9 | issue= 1 | pages= 33-40 | pmid=29344338 | doi=10.1177/2042018817746291 | pmc=5761955 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29344338  }} </ref>
**It is the [[aortic]] diameter corrected for body surface area and a score of more than 2.3 cm per metre square indicates a high risk of [[aortic dissection]] (2-2.3 cm per metre square is considered as moderate risk).
**The advice offered to moderate risk patients is restriction of activities and that offered to high risk patients is that they should completely avoid competitive sports and intensive weight training.
*[[Renal]] [[ultrasound]] for structural abnormalities like duplication of the collecting system and [[horseshoe shaped kidney]].
*Dual energy x-ray absorptiometry (DEXA) scans may be done to test [[bone mineral density]].
*[[Audiology]] for [[sensorineural]] and conductive hearing loss.
*Multidisciplinary [[neuropsychiatric]] evaluation should be done at major transitional stages such preschool entry and high school entry. <ref name="pmid12612263">{{cite journal| author=Frías JL, Davenport ML, Committee on [[genetics]] and Section on [[endocrinology]]| title=Health supervision for children with Turner syndrome. | journal=Pediatrics | year= 2003 | volume= 111 | issue= 3 | pages= 692-702 | pmid=12612263 | doi=10.1542/peds.111.3.692 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12612263  }} </ref>
*[[ECGs]] should be performed as [[long QT syndrome]] frequently occurs secondary to medication used to treat complications of [[Turner syndrome]].
*Individuals with a Y [[karyotypic]] abnormality should be screened with [[fluorescent insitu hybridization]] and [[polymerase chain reaction]] techniques, to detect the risk of developing a [[gonadoblastoma]].  


OR
*Laboratory investigations that may help in screening include:  <ref name="pmid20081420">{{cite journal| author=Wolff DJ, Van Dyke DL, Powell CM, Working Group of the ACMG Laboratory Quality Assurance Committee| title=Laboratory guideline for Turner syndrome. | journal=Genet Med | year= 2010 | volume= 12 | issue= 1 | pages= 52-5 | pmid=20081420 | doi=10.1097/GIM.0b013e3181c684b2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20081420  }} </ref>
*#[[serum]] [[gonadotrophins]] and [[anti Mullerian hormone]]- ovarian reserve.
*#[[renal function tests]] – [[renal failure]] secondary to structural abnormalities.
*#[[Thyroid function tests]] – [[thyroiditis]], [[hypothyroidism]], [[hyperthyroidism]]
*#[[liver function tests]] – [[focal nodular hyperplasia]]
*#[[serum]] IgA, [[IgA anti endomysium antibodies]] and [[IgA antigliadin antibodies]] – [[Celiac disease]]
*#Lipid profile – [[hyperlipidemia]]
*#Oral glucose tolerance test and [[serum]] [[glycosylated hemoglobin]] – for type 2 [[diabetes mellitus]].
*#[[serum]] 25-hydroxyvitamin D- [[Vitamin D deficiency]].


According to the [guideline name], screening for [disease name] is not recommended.


OR


According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
== 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines<ref name="pmid30121240">{{cite journal| author=Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM | display-authors=etal| title=2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. | journal=J Am Coll Cardiol | year= 2019 | volume= 73 | issue= 12 | pages= 1494-1563 | pmid=30121240 | doi=10.1016/j.jacc.2018.08.1028 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30121240  }}</ref> ==
*[Condition 1]
*[Condition 2]
*[Condition 3]


=== Diagnostic and Therapeutic Recommendations for Turner Syndrome ===
{| class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen" |[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen" |'''1.'''Women with Turner syndrome should be evaluated for bicuspid aortic valve, coarctation of the aorta, and enlargement of the ascending aorta. ''(Level of Evidence: B-NR)''
|}
{| class="wikitable"
|-
| colspan="1" style="text-align:center; background:LemonChiffon" |[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
| bgcolor="LemonChiffon" |'''1.'''Prophylactic replacement of the aortic root or ascending aorta in adults with Turner syndrome is reasonable when the aortic diameter is 2.5 cm/m2 or greater.
''(Level of Evidence: B-NR)''
|}
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
Line 34: Line 60:




[[Category:Medicine]]
[[Category:Up-To-Date]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Genetic disorders]]
[[Category:Genetic disorders]]
[[Category:Syndromes]]
[[Category:Syndromes]]
[[Category:Mature chapter]]

Latest revision as of 18:56, 15 December 2022

Turner syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Turner syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Turner syndrome screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Turner syndrome screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Turner syndrome screening

CDC on Turner syndrome screening

Turner syndrome screening in the news

Blogs on Turner syndrome screening

Directions to Hospitals Treating Turner syndrome

Risk calculators and risk factors for Turner syndrome screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akash Daswaney, M.B.B.S[2]

Overview

Screening for complications of Turner syndrome starts as early as a prenatal visit. Abnormal maternal serum screening tests or an ultrasound detecting structural anomalies such shortened limbs, cystic hygromas, congenital heart defects or increased swelling of the hands or feet may point towards a diagnosis of Turner syndrome. As the years progress, screening involves a multidisciplinary combination of lab investigations (such as serum gonadotrophins, liver function tests, renal function tests, etc), referral to other departments (cardiology, endocrinology, ophthalmology, etc) and tools such as DEXA scans, X-rays, echocardiography, etc.

Screening


2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[4]

Diagnostic and Therapeutic Recommendations for Turner Syndrome

Class I
1.Women with Turner syndrome should be evaluated for bicuspid aortic valve, coarctation of the aorta, and enlargement of the ascending aorta. (Level of Evidence: B-NR)
Class IIa
1.Prophylactic replacement of the aortic root or ascending aorta in adults with Turner syndrome is reasonable when the aortic diameter is 2.5 cm/m2 or greater.

(Level of Evidence: B-NR)

References

  1. Shankar RK, Backeljauw PF (2018). "Current best practice in the management of [[Turner syndrome]]". Ther Adv Endocrinol Metab. 9 (1): 33–40. doi:10.1177/2042018817746291. PMC 5761955. PMID 29344338. URL–wikilink conflict (help)
  2. Frías JL, Davenport ML, Committee on genetics and Section on endocrinology (2003). "Health supervision for children with Turner syndrome". Pediatrics. 111 (3): 692–702. doi:10.1542/peds.111.3.692. PMID 12612263.
  3. Wolff DJ, Van Dyke DL, Powell CM, Working Group of the ACMG Laboratory Quality Assurance Committee (2010). "Laboratory guideline for Turner syndrome". Genet Med. 12 (1): 52–5. doi:10.1097/GIM.0b013e3181c684b2. PMID 20081420.
  4. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM; et al. (2019). "2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". J Am Coll Cardiol. 73 (12): 1494–1563. doi:10.1016/j.jacc.2018.08.1028. PMID 30121240.

Template:WH Template:WS